Filing Flows

Filing Flows › 8-K events › Lenz Therapeutics

Lenz Therapeutics: results of operations

Form 8-K filed Oct 28, 2026 · items 2.02, 5.02

CEO changesLENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession

What the filing says

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Item 5.02: −0.1% next session across 39,174. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Lenz Therapeutics at a glance

Latest quarterQ3 2026
Revenue$3.4M
Revenue Y/Y-73%
Operating margin-972.8%
IndustryBiological Products, (No Diagnostic Substances)

Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%. The chart follows the revenue to costs, profit and cash.

Lenz Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.